Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials

Abstract

Expert Rev. Cardiovasc. Ther. 8(9), 1207–1210 (2010) “Two trials with the everolimus-eluting stent demonstrated a significant reduction in angiographic in-stent and in-segment late lumen loss compared with the first-generation TAXUS Express paclitaxel-eluting stent, and noninferiority in major clinical end points…”